Related Experiment Video

Updated: Jul 14, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway signaling

Andrew Thorburn1

  • 1Department of Pharmacology and University of Colorado Comprehensive Cancer Center, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado 80010, USA. Andrew.Thorburn@uchsc.edu

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|June 5, 2007
PubMed

Insights

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine crucial for tumor surveillance. This review explores TRAIL pathway signaling for cancer treatment strategies.

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine that initiates apoptosis via cell surface death receptors.
  • TRAIL plays a role in host tumor surveillance and suppressing metastasis.
  • Therapeutic agents targeting TRAIL receptors for cancer treatment are under clinical investigation.

Purpose of the Study:

  • To review recent advancements in understanding TRAIL pathway signaling.
  • To connect TRAIL signaling mechanisms with challenges in cancer therapy.
  • To inform strategies for manipulating TRAIL signaling in oncology.

Main Methods:

  • Literature review of recent findings on TRAIL pathway signaling.
  • Analysis of signaling mechanisms related to TRAIL receptor activation.
  • Discussion of therapeutic implications for cancer treatment.

Main Results:

  • Recent findings elucidate complex TRAIL pathway signaling networks.
  • Understanding these mechanisms is key to overcoming resistance and enhancing efficacy.
  • TRAIL receptor agonists show promise but require careful consideration of signaling pathways.

Conclusions:

  • TRAIL pathway signaling is a critical target for cancer therapy.
  • Further research into TRAIL signaling mechanisms will optimize therapeutic strategies.
  • Manipulating TRAIL signaling holds significant potential for cancer treatment.

Related Concept Videos

The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...